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Background/Aims: Bioelectric nerve stimulation (eStim) is an emerging clinical
paradigm that can promote nerve regeneration after trauma, including within the context
of diabetes. However, its ability to prevent the onset of diabetic peripheral neuropathy
(DPN) has not yet been evaluated. Beyond the nerve itself, DPN has emerged as a
potential contributor to sarcopenia and bone disease; thus, we hypothesized that eStim
could serve as a strategy to simultaneously promote neural and musculoskeletal health
in diabetes.
Methods: To address this question, an eStim paradigm pre-optimized to promote nerve
regeneration was applied to the sciatic nerve, which directly innervates the tibia and
lower limb, for 8 weeks in control and streptozotocin-induced type 1 diabetic (T1D) rats.
Metabolic, gait, nerve and bone assessments were used to evaluate the progression
of diabetes and the effect of sciatic nerve eStim on neuropathy and musculoskeletal
disease, while also considering the effects of cuff placement and chronic eStim in
otherwise healthy animals.
Results: Rats with T1D exhibited increased mechanical allodynia in the hindpaw,
reduced muscle mass, decreased cortical and cancellous bone volume fraction (BVF),
reduced cortical bone tissue mineral density (TMD), and decreased bone marrow
adiposity. Type 1 diabetes also had an independent effect on gait. Placement of the
cuff electrode alone resulted in altered gait patterns and unilateral reductions in tibia
length, cortical BVF, and bone marrow adiposity. Alterations in gait patterns were
restored by eStim and tibial lengthening was favored unilaterally; however, eStim did
not prevent T1D-induced changes in muscle, bone, marrow adiposity or mechanical
sensitivity. Beyond this, chronic eStim resulted in an independent, bilateral reduction
in cortical TMD.
Conclusion: Overall, these results provide new insight into the pathogenesis of diabetic
neuroskeletal disease and its regulation by eStim. Though eStim did not prevent
neural or musculoskeletal complications in T1D, our results demonstrate that clinical
applications of peripheral neuromodulation ought to consider the impact of device
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placement and eStim on long-term skeletal health in both healthy individuals and
those with metabolic disease. This includes monitoring for compounded bone loss
to prevent unintended consequences including decreased bone mineral density and
increased fracture risk.
Keywords: bone, nerves, neuropathy, electrical stimulation, muscle, type 1 diabetes (T1D), gait, bone marrow
adiposity
INTRODUCTION
Therapeutic use of electrical stimuli, or bioelectric medicine,
is ancient. For centuries, humans have exploited the responses
of the body to electrical stimuli for medical treatment, starting
with pain and expanding to increasingly complex disorders from
hearing loss to paralysis (Chang, 2021). Bioelectric medicine has
also provided solutions to musculoskeletal disease and injury.
For example, electrical current delivered to nearby bone fractures
can enhance healing outcomes (Aleem et al., 2016), and long,
thin electrodes implanted near the spine or peripheral nerves
can relieve chronic back or joint pain (Kapural et al., 2016; Ilfeld
et al., 2019; Deer et al., 2021). Additionally, electrical stimulation
of peripheral nerves (eStim) offers a unique opportunity to
utilize the interconnectedness and regulatory function of the
nervous system to treat diverse conditions throughout the body.
For example, one of the most widely applied therapeutics in
bioelectric medicine today is vagus nerve stimulation. Promising
results have been shown for both rheumatoid arthritis and obesity
in using eStim to harness the anti-inflammatory and satiety-
mediating functions of the vagus nerve (Koopman et al., 2016;
Apovian et al., 2017).
In the past two decades, eStim paradigms that enhance the
regenerative capacity of nerves in rodents and humans post-
injury have also been established. In rats and mice, both motor
and sensory nerves demonstrate upregulated regeneration-
associated genes with application of eStim (Brushart et al., 2005;
Geremia et al., 2007; Gordon and English, 2016). In humans, one
application of post-surgical eStim similarly improves functional
nerve regeneration after repair of digital nerve transection
and median nerve crush injury (i.e., carpal tunnel syndrome)
(Gordon et al., 2010; Wong et al., 2015). Studies in mice and
rats suggest that the neuroregenerative effects of eStim post-
injury persist even in the metabolically challenged state of
streptozotocin (STZ)-induced type 1 diabetes (T1D) (Lin et al.,
2015; Singh et al., 2015).
In this study, we hypothesized that a neuroregenerative
eStim paradigm may be sufficient to halt the progression
of diabetic peripheral neuropathy (DPN), contributing to
restoration of function. Considering correlations between neural
and musculoskeletal health in diabetes (Melendez-Ramirez et al.,
2010; Forbes and Cooper, 2013; Jaiswal et al., 2017; Beeve
et al., 2019), we also hypothesized that eStim would provide
a simultaneous benefit for innervated downstream organs,
including muscle and bone, in both control and diabetic rats.
To test this hypothesis, we utilized a fully implantable, wireless
system for sciatic nerve stimulation that has previously been
employed to promote nerve regeneration (MacEwan et al., 2018).
This technology enabled us to deliver weekly 1 h eStim treatments
for 8 weeks with a silicone nerve cuff electrode. Coupled with
metabolic, neural and musculoskeletal analyses, our experimental
design allowed us to determine the in vivo effect of chronic eStim
on nerve, muscle and bone in the context of health and diabetes.
This work was completed as part of the National Institutes of
Health SPARC consortium (Stimulating Peripheral Activity to
Relieve Conditions) in the United States.
MATERIALS AND METHODS
eStim Device Fabrication
Fully implantable sciatic nerve cuff stimulators were fabricated
as previously described (MacEwan et al., 2018). Braided Pt/Ir
leads (10IR9/49T, Medwire, Sigmund Cohn Corp.) were threaded
through 8 mm of silicone tubing (inner diameter 1.5 mm)
using a custom plastic rig (Figures 1A,B). Exposed wires on the
external surface of the silicone cuff were insulated with medical-
grade silicone elastomer (A-564, Factor II). Cuff leads were then
soldered to a thin-film wireless receiver coil and embedded in the
same medical silicone (Figure 1A). As the average diameter of
the rat sciatic nerve is approximately 1 mm (Isaacs et al., 2014;
Onode et al., 2019), it was neither expected nor intended that the
cuff would constrict the sciatic nerve at any stage of development.
Animals
The procedures in this investigation were approved by the
Washington University Animal Studies Committee (Saint Louis,
MO, United States). Male Lewis rats (7 weeks, Strain 004)
were obtained from Charles River and housed on a 12-hour
light/dark cycle while fed ad libitum (LabDiet, 53WU, PicoLab
Rodent Diet 20).
eStim Device Implantation
All surgeries were conducted under anesthesia with 2%
isoflurane. All animals were implanted unilaterally with a device
onto the right side at 12-weeks of age. An incision was made
on the lateral surface of the right thigh to expose the sciatic
nerve. The silicone cuff was placed around the nerve and
closed with one stitch of 6-O nylon suture (McKesson, REF
S1698GX), and the receiver was placed subcutaneously proximal
to the cuff (Figure 1C, dotted circle). Device function was
verified at the time of surgery by activating the device with a
superimposed transmitter coil (Figure 1C, white coil) and the
implant site muscle and skin layers were closed with 5-O Vicryl
(Ethicon, J303H) and 4-O Nylon (McKesson, REF S662GX)
suture, respectively. Animals received a single 1.0 mg/kg dose
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FIGURE 1 | Study design. (A) Drawing of the sciatic nerve cuff stimulator. (B) Outer surface (top) and inner surface (bottom) of the silicone cuff threaded with Pt/Ir
electrode leads. White arrowheads indicate horizontally threaded regions in which the electrode wire is exposed to the nerve. (C) Rat under anesthesia for eStim
treatment with location of implanted receiver indicated (dotted circle) with external power-transmitting coil (white coil). A rectal probe was inserted for thermal
monitoring (wire under tail). (D) Stimulus waveform. (E) Experimental timeline.
of buprenorphine sustained-release (ZooPharm) subcutaneously
1 h before surgery for post-operative analgesia.
Induction of Diabetes
Type 1 diabetes was induced in rats at 14-weeks of age, 2 weeks
before beginning eStim treatments. A 2 week delayed-onset
treatment paradigm was selected to allow for early progression of
disease, mirroring clinical intervention for diabetic complications
such as neuropathy and bone loss that begins after diagnosis
of disease and/or onset of symptoms. Animals were fasted for
24 h on aspen bedding, after which a single 65 mg/kg dose
of STZ was administered by IP injection. Controls received
saline vehicle. After injection, fasting was continued for 2 h
prior to returning food and 10% sucrose filter-sterilized water
was provided ad libitum for 24 h. After 24 h, the rats were
returned to cobb bedding and filtered water. Body mass and
tail blood glucose were monitored daily after STZ injection
with an electronic scale and with a tail prick by blood
glucometer (Bayer Contour Next) for 3 days post-injection.
Blood glucose and body mass were subsequently recorded
weekly for all animals. Rats exhibiting successive reductions in
weight and bradykinesia were given biweekly 2 mL subcutaneous
saline injections, wet food and hydrogel until stable body
mass was restored.
eStim Treatment Regimen
Beginning at 16-weeks of age and continuing for 8 weeks total,
those animals assigned to the stimulation group were treated
weekly for 1 h with a supramaximal cathodic square pulse,
0.2 ms pulse duration, and 20 Hz frequency (Figure 1D).
Animals were anesthetized with 2% isoflurane and placed on
a heating pad throughout treatment. These parameters were
previously shown to enhance neural regrowth post-transection
(Geremia et al., 2007; MacEwan et al., 2018). Sham animals
received only anesthesia, also weekly for 1 h. Body temperature
was monitored in all animals with a rectal thermometer probe
(Extech Instruments Easy View 10, Figure 1B, wire under tail).
Treatments began 2 weeks post-STZ and continued for 8 weeks
prior to end point analysis at 24 weeks of age (Figure 1E).
There were four experimental groups in this study: control sham,
control eStim, T1D sham, and T1D eStim.
At the start of the experiment, all animals showed maximal
activation of muscles in the lower limb at a stimulation amplitude
of 8–9 V. Maximal muscular activation was defined visually by
pointed toes and clenched paw and by palpating twitches in
the tibialis anterior and gastrocnemius muscles (Supplementary
Video 1). Upon implantation of a neuroprosthetic device, it was
expected that some fibrotic encapsulation would occur that might
affect the magnitude of muscle activation over time. Therefore,
muscular contraction was assessed visually and by palpation
during each week of eStim for each animal to ensure that the
stimulations achieved this maximally activated effect. If the effect
was not achieved by the initial stimulus intensity, it was increased
by raising first the voltage and then the pulse duration in order to
maintain the maximally activated muscle contraction observed at
the start of the experiment.
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Single Frame Motion Analysis
Single frame motion analysis (SFMA) was performed at 10- and
23-weeks of age. Animals were trained to walk across a 3-foot-
long, 3.5-inch wide wooden plank to their home cage by placing
them on the plank at increasingly distant positions from their
home cage. Tickling was used as a reward for task completion
(Cloutier et al., 2018). Once animals were adequately trained
to walk from the most distant end of the plank to their home
cage without pausing, the animals were recorded from behind
(iPhone X). Video analysis was performed in MATLAB using
a custom guided-user interface designed to measure the first-
quadrant angle between the horizontal axis and the foot-to-base
vector – this parameter is called the foot-to-base angle (FBA) (Fey
et al., 2010). The horizontal axis was determined by the edge of
the home cage. The foot-to-base vector was measured by drawing
a line between the heel and the midplantar surface at a frame just
before pushoff. The angle was measured for every frame available
for each foot while the animal was actively walking.
Von Frey
The up-down method was used to assess mechanical allodynia
in all animals at 23-weeks of age (Chaplan et al., 1994). Animals
were placed on a chicken-wire metal grid fixed to a wooden
frame. The frame was elevated 1.5-feet above a countertop to
allow for testing and viewing the plantar surface of the paw.
A mouse cage was placed over the animal to restrain motion.
Animals were allowed to acclimate for 5 min, at which point they
were no longer actively exploring their environment. Manual von
Frey monofilaments ranged from 8 to 300 g force. A response
was recorded as hindpaw withdrawal upon or subsequent to
application of the filament. Filaments were applied on alternating
sides as described previously, and after a response, animals
were allowed to reacclimate for 1 min before the applying
the next filament.
In vivo Computed Tomography: Cortical
Bone
All animals were scanned in vivo at 12- and 24-weeks of age.
Animals were anesthetized with 1–2% isoflurane and placed into
the scanning bed. A piece of VetWrap bandage was taped over
the animal’s torso to reduce loss of body heat. The top limb was
placed into a rig to straighten and stabilize the leg during the scan
with the foot secured. In vivo scans were conducted on the mid-
diaphysis: a 3 mm region (200 slices) centered halfway between
the proximal end of the tibia and the tibiofibular junction
(VivaCT40; Scanco Medical; 70 kVp; 114 uA; 15 µm voxel size).
After the first limb was scanned, the animal was rotated on the
bed and the scan process was repeated for the contralateral limb.
The total time under anesthesia exceeded no more than 1 h.
Analysis was performed using the Scanco software. The entire
3 mm ROI at the mid-diaphysis was contoured and analyzed at
a threshold of 250 with sigma and support values of 0.8 and 1,
respectively. Bone volume fraction (BV/TV), cortical thickness
(mm), tissue mineral density (mg HA/cm3), total area (mm2),
bone area (mm2), medullary area (mm2), and pMOI (mm4) were
extracted for data analysis.
Ex vivo Computed Tomography:
Cancellous Bone
Prior to sectioning for histology, explanted tibias were embedded
in 2% agarose, and a 6 mm region was scanned starting
at the growth plate (VivaCT40; Scanco Medical; 70 kVp;
114 uA; 15 µm voxel size). Analysis was performed using
the Scanco software. From 2 mm (133 slices) below the
growth plate, an ROI of 1.5 mm (100 slices) was contoured
and analyzed at a threshold of 240 with 0.8 sigma and 1
support. Total volume (mm3), bone volume (mm3), bone
volume fraction (BV/TV), structural model index (SMI),
connectivity density, trabecular number, trabecular thickness
(mm), trabecular separation (mm), and tissue mineral density
(mg HA/cm3) were extracted for analysis.
Histology and Bone Marrow Adipocyte
Analysis
At the end point (24 weeks), rats were euthanized via
carbon dioxide overdose followed by pneumothorax.
Tissues were collected and weighed on an electronic scale.
Collected tissues were fixed in 10% neutral buffered formalin
(Fisher Scientific 23-245684) for 24 h prior to processing
as detailed below. Tibia length was measured with digital
calipers (iKKEGOL).
All histology was performed by the WUSM Musculoskeletal
Histology and Morphometry core. Prior to embedding, tibias
were dehydrated in a reverse gradient to 70% ethanol. Tibias
were bisected transversely at the 50% site between the proximal
end and the tibiofibular junction and approximately 2 mm below
the growth plate to achieve cross-sections corresponding to our
regions of CT analysis. Bones were fully decalcified in 14% EDTA
(Sigma-Aldrich E5134), pH 7.4 prior to paraffin embedding,
sectioning (10 µm thickness) and staining with hematoxylin
and eosin. Images were taken on a Hamamatsu 2.0-HT Nano
Zoomer System with NDP.scan 2.5 image software at 20× in
bright field mode.
The acquired images were exported as TIFF files under 10×
magnification and were processed in Fiji to measure average
adipocyte cell size and number. Briefly, the scale in Fiji was first
set to be consistent with the original image (1.084 pixels/µm).
The image was then converted to 8-bit and the cortical bone was
specifically selected by thresholding. A median filter with a radius
of 10 pixels was applied. The image was then inverted and the
area of bone marrow cavity was selected and measured using the
“Wand tool” and the “Measure” command. A threshold of 230
to 255 was applied to the original 8-bit image and everything
outside the bone marrow cavity was cleared using the “Clear
Outside” command. A median filter with a radius of two pixels
was applied to the image and the non-adipocyte structures were
selected and eliminated using the “Analyze Particles” tool by
setting the circularity to 0–0.2. The cleaned image was further
processed using the “Watershed” tool and the adipocyte size and
number were finally determined using the “Analyze Particles”
tool by setting the size to 200 to 4000 µm2 and circularity to
0.50–1.00. The average adipocyte cell size and number per bone
marrow area were calculated using Excel.
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Statistics
Statistical analyses for this study were performed in GraphPad
Prism. Tests included two-way ANOVA, three-way ANOVA,
and mixed effects analyses. Specific information on statistical
tests is detailed in the figure legends. A p-value of less
than 0.050 was considered statistically significant. Quantitative
assessments including bone length, organ mass, microcomputed
tomography, behavioral assessments, and bone marrow adiposity
measurements were performed by individuals blinded to the
experimental groups.
RESULTS
Regulation of Blood Glucose, Body, and
Tissue Mass by T1D and eStim
Blood glucose and body mass were monitored longitudinally
to confirm diabetic induction and sustained hyperglycemia
throughout the study. In T1D rats, blood glucose increased from
106± 7 to 503± 70 mg/dL post-injection with STZ (Figure 2A).
Sustained hyperglycemia was maintained throughout the course
of the experiment (Figure 2A). By contrast, control animals
remained normoglycemic (Figure 2A). From the time of T1D
onset at 14-weeks of age to the final week of treatment, body
mass increased by 28 ± 4% in control animals and decreased
by 23 ± 4% in diabetic animals relative to baseline (Figure 2B).
As expected, unilateral sciatic nerve eStim for 1 h per week
did not influence body mass or blood glucose in healthy
or diabetic animals, relative to sham, anesthesia-only controls
(Figures 2A,B).
At the end point, tissues including liver, gonadal white adipose
tissue (gWAT), and spleen were dissected and weighed to gauge
overall health. Type 1 diabetes resulted in reduced absolute liver
and gWAT mass (Figures 2C,E). When normalized to body
weight, liver mass was elevated by 37% in T1D rats (Figure 2D)
and the relative quantity of gWAT was reduced by 78%
(Figure 2F). Bioelectric nerve stimulation resulted in reduced
absolute liver mass, but normalization to body weight eliminated
this effect (Figures 2C,D). Bioelectric nerve stimulation did not
alter gWAT (Figures 2E,F). Type 1 diabetes caused absolute
decreases in spleen mass that were proportional to body size and
not impacted by eStim (data not shown). Overall, this confirmed
that intermittent, unilateral stimulation of the sciatic nerve did
not cause overt global changes in peripheral tissues.
Stimulation of the sciatic nerve causes unilateral muscle
contraction (Supplementary Video 1). We hypothesized that this
may be sufficient to increase muscle mass in healthy animals
and to rescue muscle atrophy in those with T1D. In previous
studies, type II (fast-twitch) muscle fibers and type I (slow-
twitch) fibers were differentially regulated by T1D in the STZ-
induced model (Rutschmann et al., 1984; Cotter et al., 1989).
Thus, muscles of predominately type I [soleus (SOL)], type
II [tibialis anterior (TA), extensor digitorum longus (EDL),
plantaris (PL)] and mixed type fiber compositions [lateral and
medial gastrocnemius (LGC/MGC)] were selected for analysis
(Figure 3A). Rats with T1D had reduced hindlimb muscle
mass relative to controls (Figures 3B–F). Specifically, in diabetic
animals, muscle masses were bilaterally reduced by 32% in the
soleus (Figure 3B); by 56, 60, and 54% in the tibialis anterior,
EDL, and plantaris, respectively (Figures 3C–E); and by 53% in
the gastrocnemius (Figure 3F). Consistent with previous reports
(Rutschmann et al., 1984; Cotter et al., 1989), muscles containing
a significant population of type II fibers were more severely
affected by diabetes than muscles with predominately type I
fibers. In addition to the effect of diabetes, we also considered
the effects of sciatic nerve cuff placement and eStim using three-
way ANOVA (T1D × Cuff × eStim). The placement of a
sciatic nerve cuff did not independently influence muscle mass.
In addition, contrary to our expectations, eStim treatment did not
significantly alter or improve muscle mass in control rats or those
with T1D (Figures 3B–F).
Gait Alterations and Mechanical
Allodynia With T1D, Sciatic Nerve Cuff,
and eStim
As the sciatic nerve is involved in locomotion, its manipulation
could result in gait changes. For example, FBA is reduced
in rodents with sciatic nerve damage (Fey et al., 2010). To
assess this, single-frame motion analysis was conducted at 10-
and 23-weeks of age. Foot-to-base angle was measured as the
first-quadrant angle between the line from midplantar surface
to heel and the perpendicular (home cage edge) (Figure 4A;
Fey et al., 2010; Kruspe et al., 2014). At baseline, prior to
surgery, FBA was not significantly different between the left
and right limbs (Figure 4B). At the end point, T1D resulted
in a bilateral reduction of FBA by −12%, independent of cuff
placement or eStim (Figure 4C). Foot-to-base angle was further
reduced unilaterally on the cuffed side of non-stimulated animals
by −12 ± 10% in controls and by −13 ± 14% in diabetics
(Figure 4C). In stimulated animals, however, this effect was
suppressed. The FBA of the cuffed limb was partially restored in
control and diabetic eStim groups to −3 ± 7 and −3 ± 13%,
respectively, relative to the control side (Figure 4C). Overall,
these results show a unilateral, detrimental effect of sciatic nerve
cuffing on gait that is partially restored by eStim.
Rodent models of T1D exhibit mechanical allodynia,
representative of sensory DPN (Morrow, 2004). We hypothesized
that application of neuroregenerative eStim would oppose the
progression of DPN, resulting in normalization of mechanical
sensitivity. Cuff placement can also independently cause
unilateral sensitivity if placed too tightly around the nerve
(Mosconi and Kruger, 1996; Austin et al., 2012). Thus, we
measured mechanical allodynia at 23-weeks of age (one week
before end point) using manual von Frey filaments applied to
the mid-plantar surface of the hindpaw [Figure 4D, red oval;
(Chaplan et al., 1994)]. As expected, diabetic animals exhibited,
on average, a 56% reduction in the response threshold bilaterally
compared to controls, indicative of increased sensitivity to
mechanical stimuli (Figure 4E, three-way ANOVA, T1D
p = 0.0026). However, contrary to our expectations, eStim
treatment did not alter the mechanical sensitivity of the controls
or rescue the mechanical allodynia of those with T1D (Figure 4E,
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FIGURE 2 | Blood glucose and body and organ mass. Blood glucose and body mass were evaluated starting at the time of STZ induction (14-week of age) up to
the final week of treatment (24-week of age). (A) Blood glucose. (B) Body mass. (C) Liver mass at end point. (D) Liver mass normalized to body mass. (E) Gonadal
white adipose tissue (gWAT) mass at end point. (F) gWAT mass normalized to body mass. Statistics for blood glucose and body mass were performed by mixed
effects and three-way ANOVA analyses, respectively, as a single missing value was present in the blood glucose data; Control, sham n = 7; Control, eStim n = 6;
Diabetic, sham n = 8; Diabetic, eStim n = 5; *p < 0.050. Statistics for organ masses was performed by two-way ANOVA with Sidak’s multiple comparisons test;
Control, sham n = 3; Control, eStim n = 3; Diabetic, sham n = 4; Diabetic, eStim n = 3; *p < 0.050.
three-way ANOVA, eStim p = 0.6957). The presence of the
unilateral sciatic nerve cuff also did not impact the mechanical
sensitivity in the cuffed limb in either control or diabetic animals,
confirming the absence of overt nerve constriction or irritation
in our model (three-way ANOVA, Cuff p = 0.6964).
Changes in Bone and Bone Marrow
Adiposity With T1D, Sciatic Nerve Cuff,
and eStim
Bone Length
Sensory neurotransmitters such as calcitonin gene related peptide
(CGRP) have previously been shown to promote bone formation
in developing animals (Xu et al., 2020). By contrast, T1D can
limit bone growth (Silva et al., 2009). We hypothesized that
chronic nerve activation would promote bone formation in
both control and T1D animals due to increased local release of
anabolic neurotransmitters and activation of muscle contraction.
To assess the effects of T1D, cuff placement, and eStim on
skeletal growth, left and right side tibial lengths were measured
with digital calipers and compared using three-way ANOVA
(T1D × Cuff × eStim). Tibial length was decreased bilaterally by
5% in rats with T1D when compared to controls, independent
of cuff placement or eStim (Figure 5A, T1D p < 0.0001).
In addition, the cuffed limb was slightly shorter than the
non-surgical limb in sham-treated animals (−0.3 and −0.5%
Frontiers in Neuroscience | www.frontiersin.org 6 April 2021 | Volume 15 | Article 632768
fnins-15-632768 April 1, 2021 Time: 14:13 # 7
Beeve et al. Neuroskeletal Effects of Chronic eStim
FIGURE 3 | Muscle mass. At end point, muscles surrounding the tibia (A) were dissected and weighed. (B) Soleus (SOL) muscle mass. (C) Tibialis anterior (TA)
muscle mass. (D) Lateral and medial gastrocnemius (LGC, MGC) combined muscle mass. (E) Extensor digitorumlongus (EDL) muscle mass. (F) Plantaris (PL)
muscle mass. Control, sham n = 7; Control, eStim n = 6; Diabetic, sham n = 8; Diabetic, eStim n = 5; three-way ANOVA with repeated measures (Non-sx Leg vs.
Cuff Leg); *p < 0.050. Panel A generated from Charles et al. (2016).
in control and diabetic animals, respectively; Figure 5A). By
contrast, in animals treated with unilateral chronic eStim the
cuffed limb was slightly longer (+0.3 and +1.6% in control
and diabetic animals, respectively) (Figure 5A), indicating
an interaction between sciatic nerve cuffing and eStim on
longitudinal bone growth (three-way ANOVA, Cuff × eStim
p = 0.0243).
Cortical Bone
As mentioned above, sensory nerves in bone are thought
to release anabolic neuropeptides near bone-forming cells
(Tomlinson et al., 2016; Brazill et al., 2019); thus, we expected
that DPN prevention and/or neural activation by eStim would
increase bone mass. Cortical bone was analyzed by in vivo
microcomputed tomography at 12-weeks (baseline) and 24-
weeks of age (end point) in a 3 mm section of the mid-
diaphysis, centered between the proximal end of the tibia and
the tibia-fibula junction (Figure 5B). At baseline, prior to cuff
implantation, the left and right limbs exhibited no difference in
bone size or morphology (data not shown), although cortical
TMD was 0.8% lower, on average, in the right limb (the limb to
be cuffed) relative to the left at baseline (p = 0.0412).
At end point, rats with T1D demonstrated a 19% reduction in
cortical bone volume fraction (BVF), a 26% decrease in cortical
thickness, and a 4% decrease in cortical TMD relative to non-
diabetic controls (Figures 5C–E). Reduced bone quantity in
diabetic animals was driven by a 24% reduction in bone area,
a 7% decrease in total area, and a 16% increase in marrow area
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FIGURE 4 | Neuromuscular behavioral assessments. (A) Foot to base angle (FBA) was measured using single frame motion analysis (SFMA). (B) Baseline FBA
measurements at 10 weeks of age. (C) End point FBA measurements at 23-week of age. Manual von Frey filaments were also applied to the midplantar surface of
the hindpaw (indicated by a red circle) (D). (E) Minimum force threshold for response at end point. Statistics for baseline FBA measurements was performed by
paired t-test. Control, sham n = 7; Control, eStim n = 6; Diabetic, sham n = 8; Diabetic, eStim n = 5; three-way ANOVA with repeated measures (Non-sx Leg vs. Cuff
Leg); *p < 0.050.
(Figures 5F–H). Sciatic nerve cuffing over 12 weeks had a small
negative effect on cortical BVF in the cuffed limb (ranging from
−0.4 to −1.5%), independent of eStim or T1D (Figure 5C).
This effect was also reflected by a unilateral 1 to 3% reduction
in bone area in the cuffed limb relative to the non-surgical
control side (Figure 5G). The only observed effect of eStim on
cortical bone was a 0.6 and 1.6% bilateral reduction in TMD
in control and diabetic animals, respectively, relative to non-
stimulated, sham controls (Figure 5E). In summary, T1D resulted
in reduced cortical bone quantity and mineral density that was
not rescued by eStim. In fact, eStim and sciatic nerve cuffing
introduced additional cortical bone deficits in both control and
diabetic animals including bilaterally reduced TMD (as a result
of eStim) and unilaterally reduced bone mass (as a result of
sciatic nerve cuffing).
Cancellous Bone
Long bones are filled with spongy, cancellous bone that is
concentrated largely at the metaphyses. This bone has a
high turnover rate and is susceptible to systemic change,
including well-documented decreases in rodents with T1D
(Silva et al., 2009). To assess the effects of T1D, cuff placement
and eStim on metaphyseal cancellous bone, we analyzed a 1.5 mm
region starting 2 mm below the growth plate (Figure 6A).
Consistent with previous reports, cancellous BVF was reduced by
31% in rats with T1D (Figure 6B). This was associated with a 10%
increase in trabecular number and a 25% decrease in trabecular
thickness (Figures 6C,D). Animals with T1D exhibited a trending
20% reduction in connectivity density (data not shown; three-
way ANOVA, p = 0.0651) and a significant increase in structure
model index (SMI) (Figure 6E; 2.6 vs. 3.1; SMI = 0 for plates, 3
for rods and 4 for solid spheres). Cancellous bone mineral density
(BMD) was not significantly different between groups (data not
shown). Unlike the effects observed with T1D, cancellous bone
quantity, morphology, and mineralization were not modified by
sciatic nerve cuffing or chronic eStim.
Bone Marrow Adiposity
In addition to bone, the skeleton is filled with a unique
population of adipocytes that are collectively known as the
bone marrow adipose tissue (BMAT). Bone marrow adipose
tissue is an emerging regulator of hematopoietic, metabolic
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FIGURE 5 | Tibia length and cortical bone. (A) End point tibial length as assessed after dissection using digital calipers. Cortical bone was evaluated at 24-week of
age by µCT in a 3 mm region centered midway between the proximal end of the tibia and the tibia-fibula junction (B). (C) Cortical bone volume fraction (BV/TV).
(D) Cortical thickness. (E) Cortical tissue mineral density (TMD). (F) Cortical total area. (G) Cortical bone area. (H) Cortical marrow area. Control, sham n = 7;
Control, eStim n = 6; Diabetic, sham n = 8; Diabetic, eStim n = 5; three-way ANOVA with repeated measures (Non-sx Leg vs. Cuff Leg); *p < 0.050.
FIGURE 6 | Cancellous bone. Cancellous bone was analyzed 2 mm below the growth plate in a 1.5 mm region (A), dotted line represents contour inside of which
bone was analyzed. (B) Cancellous bone volume fraction (BV/TV). (C) Trabecular number. (D) Trabecular thickness. (E) Structural model index (SMI). Control, sham
n = 7; Control, eStim n = 6; Diabetic, sham n = 8; Diabetic, eStim n = 5; three-way ANOVA with repeated measures (Non-sx Leg vs. Cuff Leg); *p < 0.050.
and skeletal health (Scheller et al., 2016). The ability of nerve
stimulation to regulate bone marrow adipocytes in vivo remains
unknown. In this study, bone marrow adipocytes were analyzed
in the metaphysis approximately 2 mm below the growth plate
(Figures 7A–C) and in the diaphysis approximately 2 mm above
the peak of the tibial crest (Figures 7D–F), matching our regions
of skeletal morphologic assessment in Figures 5, 6, respectively.
Type 1 diabetes and sciatic nerve cuff placement both had
independent effects on BMAT (Figure 7); however, the effect of
sciatic nerve cuffing was region-specific. In the metaphysis, T1D
resulted in a 59% reduction in BMA number, a 63% decrease in
BMA density, and a 30% reduction in BMA size (Figures 7A–
C and data not shown). Neither sciatic nerve cuffing nor eStim
resulted in a change in metaphyseal BMAT. In the diaphysis,T1D
similarly, resulted in a 39% reduction in BMA number, a 59%
decrease in BMA density, and a 19% reduction in BMA size
Frontiers in Neuroscience | www.frontiersin.org 9 April 2021 | Volume 15 | Article 632768
fnins-15-632768 April 1, 2021 Time: 14:13 # 10
Beeve et al. Neuroskeletal Effects of Chronic eStim
FIGURE 7 | Bone marrow adipose tissue. Bone marrow adiposity was analyzed in the metaphysis 2 mm below the growth plate and in the mid-diaphysis. (A) BMAT
histology in the metaphysis in healthy and control animals. (B) Adipocyte density in the metaphysis. (C) Average adipocyte size in the metaphysis. (D) BMAT
histology in the diaphysis in health and control animals. (E) Adipocyte density in the diaphysis. (F) Average adipocyte size in the diaphysis. B = bone; cs = central
venous sinus. Scale = 100 µm. (Control, sham n = 7; Control, eStim n = 6; Diabetic, sham n = 8; Diabetic, eStim n = 5) three-way ANOVA with repeated measures
(Non-sx Leg vs. Cuff Leg); *p < 0.050.
(Figures 7D–F and data not shown). However, contrary to the
metaphyseal data, sciatic nerve cuffing alone also caused a 5–32%
reduction in BMA number, a 5–38% reduction in BMA density,
and a 4–12% reduction in adipocyte cell size relative to the
contralateral limb (Figures 7D–F and data not shown). These
cuff-side effects on bone marrow adiposity were driven primarily
by changes in the non-diabetic control group and align spatially
with previously reported differences in the innervation of the
bone marrow adipocyte population along the length of the limb
(Wee et al., 2019). Bioelectric stimulation did not modify the
effects of T1D or cuff placement on bone marrow adiposity.
DISCUSSION
Despite promising results showing the pro-regenerative benefits
of eStim (Geremia et al., 2007; Wong et al., 2015; Gamble
et al., 2016), studies to date have not addressed its utility to
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prevent the onset of neuropathic symptoms and musculoskeletal
decline in the context of metabolic diseases like T1D. Our
experimental design allowed us to address the above questions
using a fully implantable, wireless sciatic nerve stimulation
device in a rat model of T1D while also considering the
effects of cuff placement and chronic eStim in otherwise
healthy animals.
Rodent models of T1D are characterized by progressive
increases in mechanical sensitivity in addition to deficits in bone
quantity, muscle mass and neuromuscular function (Cotter et al.,
1989; Morrow, 2004; Silva et al., 2009). Similar to previous
studies, we observed a significant decrease in hindlimb muscle
mass, reduced withdrawal threshold to mechanical stimuli in
the hindpaw, changes in gait, and substantial decreases in bone
in animals with T1D. These results are entirely consistent with
previous studies with one exception. Previous reports of STZ-
induced T1D in rodents have demonstrated an increase in bone
marrow adiposity and a decrease in peripheral fat mass (Botolin
et al., 2005; Martin and McCabe, 2007). While we did observe
a significant reduction in peripheral fat, we did not observe
an increase in tibial bone marrow adipocyte density or size
in either the metaphysis or diaphysis of rats after 10 weeks
of STZ-induced T1D. In fact, contrary to prior results, both
adipocyte density and size were substantially reduced in diabetic
rats. Previous findings were observed in mice at 4- to 6-weeks
post-induction; thus, our results may indicate a differential effect
on bone marrow adiposity with sustained T1D that warrants
further investigation.
In our study we also assessed the effect of chronic placement
of a silicone sciatic nerve cuff for 12 weeks. We found that
cuff placement contributed to independent changes in gait,
tibial length, cortical bone and bone marrow adiposity. Cuff
placement can be used as a model of chronic constriction injury
(CCI) and neuropathic pain, but the largest inner diameter
used in CCI models is approximately half of that used in
our device (0.86 vs. 1.5 mm) (Mosconi and Kruger, 1996;
Balasubramanyan et al., 2006; Austin et al., 2012). In addition,
we did not see a unilateral increase in mechanical sensitivity
induced by the placement of a sciatic nerve cuff, a typical
indicator of neuropathy in CCI studies. Thus, it is unlikely
that the effects on gait and bone were caused by overt nerve
constriction. Instead, we anticipate that these results reflect local
changes in nerve swelling, fibrosis and inflammation that occur
after implantation of a local neuroprosthesis, contributing to
the observed changes in gait and tibia length and unilateral
reductions in cortical bone mass and bone marrow adiposity.
Indeed, upon dissection, we observed that the sciatic nerve
cuff implanted in all animals, regardless of glycemic condition
or eStim, was enveloped in fibrotic tissue that fixed the cuff
in place. To reduce activation of inflammatory responses and
improve flexibility, more sophisticated designs for chronic
neural implants are available. Extraneural electrodes like the
one used herein are preferred (Günter et al., 2019), but
helical or spiral cuff designs can provide more flexibility
and relieve any tension or strain on the nerve (Naples
et al., 1988; Christie et al., 2017). Noninvasive transcutaneous
stimulation of the sciatic nerve is also possible, though
reportedly ineffective for neuroregeneration (Baptista et al.,
2008). Additional research is needed to investigate whether more
flexible electrode designs would limit the undesirable effects on
bone as observed in this study.
Beyond consideration of the effects of T1D and cuff placement,
the primary goal of this study was to isolate the impact of
chronic, intermittent eStim on nerve and bone health and on
the progression of DPN. Contrary to our initial hypotheses,
we did not observe an effect of eStim on muscle mass, bone
quantity, or mechanical sensitivity in healthy animals or a
rescue in those with T1D. However, we did find that treatment
with eStim opposed unilateral cuff-induced effects on tibial
length and gait. This suggests that intermittent application
of a local bioelectric stimulus can counteract some of the
negative side-effects of cuff placement. Previously, the device
used herein was shown to evoke longitudinally consistent
electromyogram amplitudes in the gluteal, tibialis anterior, and
plantaris muscles over 14 weeks of implantation in healthy
animals (Gamble et al., 2016). However, inclusion of additional
functional assays such as in vivo joint torque measurements
or more comprehensive gait analyses may provide additional
insight into alterations in gait and bone caused by sciatic
nerve cuffing and opposed by eStim. Local, stimulation-induced
release of anabolic neuropeptides at the growth plate may also
be involved in promoting unilateral tibial lengthening (Brazill
et al., 2019). Additionally, bioelectric nerve stimulation has
been shown to drive changes in muscular gene expression
(Brownson et al., 1988); which may also underlie functional
changes observed in gait independent of muscle mass. Future
investigation is required to determine if eStim modulates
endochondral ossification at the skeletal growth plate and aspects
of muscle function, including underlying gene expression. In
addition to the possible direct effects of eStim on the growth
plate and muscle, inhibition of local neuroinflammation may
also contribute to the outcomes. While we did observe fibrosis
around the sciatic nerve cuff in all animals regardless of eStim,
we acknowledge that it remains possible that eStim locally
suppressed inflammation or fibrosis in more subtle ways than
were grossly observable. Local neuroinflammatory suppression,
in turn, may have indirectly contributed to the restoration of gait
and tibial lengthening.
Contrary to its mild restorative effects, treatment with
eStim unexpectedly resulted in a 1–2% bilateral reduction in
cortical bone tissue mineral density, independent of T1D. The
mechanism underlying this effect remains unknown. However,
we hypothesize that nerve action potentials produced by the
device used here may have travelled bidirectionally along the
axon, resulting in bilateral reductions in skeletal mineralization
through activation of central neural relays. Additional studies
may address whether this effect was centrally mediated by eStim
responses in the spinal cord or brain, or by treatment-induced
systemic stress factors otherwise insufficient to alter body mass
or blood glucose.
Limitations
The eStim paradigm employed here was previously optimized
to enhance neuroregeneration in a post-injury setting
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(Geremia et al., 2007; Singh et al., 2015; MacEwan et al.,
2018), but it was unknown if this paradigm could be leveraged to
prevent neuropathy or other musculoskeletal deficits associated
with chronic metabolic disease. While it restored cuff-induced
imbalances in gait and promoted unilateral tibial lengthening,
eStim did not prevent T1D-associated mechanical allodynia,
osteopenia, or sarcopenia. To the extent that our assays could
measure, we did not observe a benefit of eStim therapy for
nerve function in T1D animals. However, our interpretation
is limited by assay specificity. Von Frey and gait analyses
are indicative of large diameter sensory and/or motor fiber
dysfunction. While our analyses show that eStim did not
prevent large fiber neuropathy, it is left to future investigation
to determine whether eStim can protect against small-fiber
neuropathy. Our study was also limited to a discrete selection
of eStim parameters and dosing regimens. It remains possible
that increasing the number of weekly sessions or otherwise
optimizing the eStim parameters could provide additional
therapeutic benefit for nerve, muscle or bone. For example,
in a more muscle-targeted approach, shorter, daily eStim
bouts with implementation of a resting phase have been
shown to protect bone in the context of disuse osteopenia
(Lam and Qin, 2008; Lam et al., 2011; Tamaki et al., 2017).
Additionally, peripheral pain is a common application of eStim
clinically, in which parameters are typically optimized to block
aberrant nerve activity, at either the peripheral or spinal level
(Mobbs et al., 2007; Kumar et al., 2008). As such, it would be
worthwhile to assess bone health in pre-clinical and clinical
models that block neuronal activation, in addition to those
designed for activation. Last, the present study was limited to
male rats only. Sex differences have been reported in growth,
metabolism, neuropathy, and sarcopenia in STZ-induced
diabetic rodents (Vital et al., 2006; Pesaresi et al., 2011; Choi
et al., 2013; Pesaresi et al., 2018; Virgen-Ortiz et al., 2018). Bone
structural phenotypes are gender-independent in the STZ model
(Martin and McCabe, 2007), but sexual dimorphism in eStim
interaction with this phenotype may exist. Thus, it remains
unknown whether the eStim regimen employed here would be
therapeutic in female rats.
CONCLUSION
Overall, the stimulation parameters and treatment regimen
selected for this study were insufficient to prevent T1D-
induced osteopenia, sarcopenia, and neuropathy. However, our
results indicate that cuff device placement on peripheral
nerves can unilaterally reduce cortical bone mass and
tibial length and regulate bone marrow adiposity. In
addition, while bioelectric nerve stimulation restored
cuff-induced gait imbalances and unilaterally favored
tibial lengthening, it also caused bilateral reductions in
cortical bone mineral density. Altogether, this suggests that
skeletal health should be monitored in long-term clinical
applications of neuromodulation devices to prevent unintended
consequences including decreased bone mineral density and
increased fracture risk.
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